Japan's health insurance to cover ¥167 million gene therapy drug
Considered the world's most expensive medicine, relatively few cases are expected to require the one-time dosage of drug to treat spinal muscular atrophy.
Japanese government panel OKs expensive gene therapy for rare disease
A health ministry panel approved the production and sales of a gene therapy for treating spinal muscular atrophy, a rare incurable disease that destroys muscle function.
Novartis agrees to buy Medicines Co. in $6.8 billion deal targeting promising cholesterol drug
Novartis AG agreed to buy Medicines Co. for an equity value of about $6.8 billion, snapping up a promising cholesterol drug and adding to a string of acquisitions for Chief Executive Officer Vas Narasimhan. Medicines Co. shareholders will get $85 a share, Basel, Switzerland-based Novartis ...
Novartis says it knew of Zolgensma data problems before U.S. approval
Swiss Drugmaker Novartis AG on Wednesday said it knew about discrepancies in data it submitted to regulators as it sought approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed an internal investigation. Novartis faces possible civil or ...
Takeda sells dry-eye drug to Novartis for deal valued at up to $5.3 billion
Takeda Pharmaceutical Co. Ltd has agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of the U.K.'s Shire. Japan's biggest drugmaker aims to ...
Novartis ends contract with firm linked to Trump lawyer Michael Cohen, calling ties a mistake
Swiss drugmaker Novartis has ended a contract with a firm linked to U.S. President Donald Trump's lawyer, Michael Cohen, saying it was now seen as a mistake. Novartis, which has not been accused of any illegal activity, made payments totalling nearly $1.2 million to the ...
Japanese doctor who exposed a drug too good to be true calls for morality and reforms
It was a gut feeling and common sense that made Dr. Iwao Kuwajima question a drug for high blood pressure that just about every other doctor in his field was excited about in the 2000s. Kuwajima, now 72, was the first doctor in the nation ...
Novartis posts win, Roche a flop in drug trials targeting skin cancer
Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. All the medicines were tested in melanoma patients who had ...
Novartis Japan faces censure for delay in disclosing drug side effects
The health ministry will censure a Japanese unit of Swiss pharmaceutical giant Novartis AG for failing to report serious side effects from some of its drugs within a certain period of time, sources close to the matter said Wednesday. The Ministry of Health, Labor and ...
Gene therapy for deafness is moving closer to reality, with new research on Wednesday showing the technique for fixing faulty DNA can improve responses in mice with genetic hearing loss. Separately, a clinical trial backed by Novartis is under way to help a different group ...
The health ministry will order a business suspension of around 15 days for a Japanese unit of Swiss pharmaceutical maker Novartis AG for not reporting serious side effects of its drugs, sources close to the matter said on Monday. Tokyo-based Novartis Pharma K.K. would be ...
Novartis Pharma, ex-employee charged over drug data manipulation
Tokyo prosecutors charged Novartis Pharma K.K. and a former employee Tuesday with causing a medical research team to release data manipulated in favor of the firm's drug for treating high blood pressure in 2011. The prosecutors also issued a fresh arrest warrant for the former ...
